SynthesisScientific reports2022
Systematic and meta-analysis of Mycobacterium avium subsp. paratuberculosis related type 1 and type 2 diabetes mellitus.
Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multistage pathogenesis and disease associations ofFrontiers in immunology · 2026Pooled it
- Liposomal Glutathione Exhibits Direct and Intracellular Antimycobacterial Activity AgainstBioengineering (Basel, Switzerland) · 2026Article
- Advances in paratuberculosis research and control: a comprehensive expert review.BMC veterinary research · 2026Review
- Current Perspectives onInternational journal of molecular sciences · 2026Review
- Review
- Application of Biotechnology in the Synthesis of Nanoparticles-A Review.Molecules (Basel, Switzerland) · 2026Review
- Discordance between measures of Mycobacterium tuberculosis sensitization and type 2 diabetes mellitus in the United States (NHANES): A population-based cohort study.The Journal of infection · 2025Article
- Proposing Bromo-Epi-Androsterone (BEA) for Stiff Person Syndrome (SPS).Microorganisms · 2025Article
- Article
- Polymyxin sensitivity/resistance cosmopolitan status, epidemiology and prevalence among O1/O139 and non-O1/non-O139Infectious medicine · 2023Review
- InvestigatingMicrobiology spectrum · 2023Article
- Evaluation of Single Nucleotide Polymorphisms (SNPs) Associated with Genetic Resistance to Bovine Paratuberculosis inAnimals : an open access journal from MDPI · 2023Article
- Genomic epidemiology ofFrontiers in genetics · 2023Article
- Quantitative Risk Assessment of Exposure toFoods (Basel, Switzerland) · 2022Article
- Global Phylogeny ofFrontiers in microbiology · 2022Article
- Intestinal alkaline phosphatase (IAP, IAP Enhancer) attenuates intestinal inflammation and alleviates insulin resistance.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global increase in diabetes (DM) prevalence necessitated the need to establish the association between DM and environmental triggers including MAP (Mycobacterium avium subsp. paratuberculosis) that have been postulated to play a role in DM etiopathology for effective management. The present investigation aimed to assess the odds ratio (OR) presenting the association between MAP and DM. MAP-related DM studies were systematically retrieved from 6 databases until 31 September 2021 according to PRISMA principles for data abstraction. The abstracted dataset was fitted to the fixed-effects (FE) and random-effects (RE) models using the Mantel-Haenszel approach. Sixteen studies involving 2072 participants (1152 DM patients (957 type 1 diabetes mellitus (T1DM) & 195 type 2 diabetes mellitus (T2DM)) and 920 healthy controls) met the inclusion criteria. Results revealed a significant association between anti-MAP antibodies (abs) seroprevalence and T1DM (FE: OR 7.47, 95% CI 5.50-10.14, p value < 0.0001; RE: OR 7.92, 95% CI 4.39-14.31, p < 0.0001) and MAP DNA with T1DM (FE: OR 4.70 (95% CI 3.10-7.13, p value < 0.0001), RE: OR 3.90 (95% CI 0.93-16.38, p value = 0.06)). Both anti-MAP abs and MAP DNA based meta-analyses had medium heterogeneity (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.